Dr PBN Prasad To Hold Charge As DCGI On Temporary Basis

New Delhi  (ANI): Dr PBN Prasad will hold the charge of the post of Drugs Controller General of India from February 16 to 28 this year or until further orders, an official notice said on Wednesday.

According to the official notice issued by Dr Kiran Kumar Karlapu, Deputy Secretary to the Government of India, “It has been decided with the approval of the Competent Authority, that Dr PBN Prasad, JDC(I) shall hold the charge of the post of Drug Controller of (India) under FR 49(v)wef 16.02.2023 till 28.02.2023 (date of his superannuation) or until further orders, whichever is earlier.”

Recently, UPSC recommended the name of Dr Rajeev Singh Raghuvanshi as the new Drugs Controller General of India (DCGI).

The Union Public Service Commission (UPSC) conducted interviews for the appointment of the DCGI last week. The top contenders were Dr VG Somani, Dr Rajeev Singh Raghuvanshi and Dr Jai Prakash. According to the sources soon final name will be announced.

Earlier in November last year, Dr V G Somani’s term as Drugs controller general of India (DCGI) was extended for three months that came into effect from November 16 last year. This was done the second time, however, earlier he got an extension in the month of August 22.

Dr Kiran Kumar Karlapu, Deputy Secretary, Department of Health and Family Welfare issued the circular regarding the extension of DCGI for a further period of three months.

Dr V G Somani was appointed as Drugs Controller General of India in the month of August 2019, DCGI heads the Central Drugs Standard Control Organisation (CDSCO) which is responsible for ensuring quality drug supply across the country. It also has the authority to give approval to new drugs and regulate clinical trials. (ANI)

  • Related Posts

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    New Delhi: The Parliamentary Panel on Health and Family Welfare has recommended various significant regulatory changes in the regulation of medical devices, including decentralisation of approval for all medical devices…

    Diabetic drug metformin found to act on brain

    NEW DELHI:  Cheap, effective and widely trusted, metformin has long been the first choice for treating type 2 diabetes. Now, scientists say the drug works in a way few had…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Diabetic drug metformin found to act on brain

    Diabetic drug metformin found to act on brain

    Hetero debuts semaglutide generic in emerging markets

    Hetero debuts semaglutide generic in emerging markets

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory